MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model

Vaccine

Volumn 29, Issue 24, 2011, Pages 4125-4131

  Sin, Jeong Im ^a  

^a Kangwon National University   (South Korea)

Author keywords

Adaptive immunity; Antitumor immunity; DNA vaccines; Human papillomavirus; MyD88

Indexed keywords

ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; MYELOID DIFFERENTIATION FACTOR 88; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTROPORATION; FEMALE; HUMAN; HUMORAL IMMUNITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL; WART VIRUS; WILD TYPE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 79956111900     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.098     Document Type: Article

References (35)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
2. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
3. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19:24-32.
4. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
5. Pavlenko M., Leder C., Moreno S., Levitsky V., Pisa P. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine 2007, 25(34):6341-6347.
6. Pasare C., Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364-368.
7. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003, 171(11):5908-5912.
8. Shedlock D.J., Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000, 68(6):793-806.
9. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Dang K., et al. CD8 positive T-cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998, 102:1112-1124.
10. Sin J.I., Sung J.H., Suh Y.S., Lee A.H., Chung J.H., Sung Y.C. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of co-injection with a granulocyte, macrophage-colony stimulating factor gene. Vaccine 1997, 15:1827-1833.
11. Sin J.I., Ayyavoo V., Boyer J., Kim J., Ciccarelli R.B., Weiner D.B. Protective immune correlates can segregate by vaccine type in a murine herpes model system. Int Immunol 1999, 11:1763-1773.
12. Kim M.S., Sin J.I. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005, 116:255-266.
13. Sin J.I. Suppression of antitumor protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 cDNA: involvement of nitric oxide in immune suppression. Immunology 2009, 128:e707-e717.
14. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999, 73:329-368.
15. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
16. Zelenay S., Elias F., Flo J. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur J Immunol 2003, 33(5):1382-1392.
17. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273(5273):352-354.
18. Schneeberger A., Wagner C., Zemann A., Lührs P., Kutil R., Goos M., et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004, 123(2):371-379.
19. Kim T.Y., Myoung H.J., Kim J.H., Moon I.S., Kim T.G., Ahn W.S., et al. Both E7 and CpG-ODN are required for protective immunity against challenge with human papillomavirus 16 (E6/E7)-immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002, 62:7234-7240.
20. Ahn W.S., Bae S.M., Kim T.Y., Kim T.G., Lee J.M., Namkoong S.E., et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003, 14(15):1389-1399.
21. Kim T.G., Kim C.H., Won E.H., Bae S.M., Ahn W.S., Park J.B., et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific anti-tumor immunity in a HPV 16 (E6/E7)-associated tumor animal model. Immunology 2004, 112:117-125.
22. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(9):2242-2249.
23. Sin J.I., Hong S.H., Park Y.J., Park J.B., Choi Y.S., Kim M.S. Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA Cell Biol 2006, 25(5):277-286.
24. Ye G.W., Park J.B., Park Y.J., Choi Y.S., Sin J.I. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther 2007, 15(8):1564-1570.
25. Lee I.H., Park J.-B., Cheong M., Choi Y.S., Park D.H., Sin J.I. Antitumor therapeutic and anti-metastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control. DNA & Cell Biol 2011, 10.1089/dna.2011.1266.
26. Neves P., Lampropoulou V., Calderon-Gomez E., Roch T., Stervbo U., Shen P., et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 2010, 33(5):777-790.
27. Chen L., Lei L., Chang X., Li Z., Lu C., Zhang X., et al. Mice deficient in MyD88 develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J Immunol 2010, 184(5):2602-2610.
28. Palliser D., Ploegh H., Boes M. Myeloid differentiation factor 88 is required for cross-priming in vivo. J Immunol 2004, 172:3415-3421.
29. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
30. Hacker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000, 192(4):595-600.
31. Hung C.F., Cheng W.F., Hsu K.F., Chai C.Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001, 61(9):3698-3703.
32. Lamikanra A., Pan Z.K., Isaacs S.N., Wu T.C., Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 2001, 75(20):9654-9664.
33. Cheng W.F., Hung C.F., Hsu K.F., Chai C.Y., He L., Polo J.M., et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002, 13(4):553-568.
34. Kaisho T., Takeuchi O., Kawai T., Hoshino K., Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001, 166(9):5688-5694.
35. Takeshita F., Tanaka T., Matsuda T., Tozuka M., Kobiyama K., Saha S., et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006, 80(13):6218-6224.